In this edition:
• Partnership activities have never been busier
• Pharma industry reorganisations
• Phylogica is not immune to industry dynamics
• Biological drugs are leading the way
• Secure financial position
• Benefitting from the new R&D tax credit legislation
• Progress with Pfizer vaccine collaboration
• Research activities underway with Janssen
More deal opportunities than ever before -
The resilience of the Phylogica team in a challenging environment has been commendable. Recent specialist international meetings have shown that Phylogica’s unique Phylomer libraries of prototype drugs are more in demand than ever before as one potential lifeline for Pharma companies seeking to carve out fresh approaches to drug discovery against challenging targets.
There is considerable interest in the field of drug targeting to the intracellular space, where Phylomers are being considered as a unique approach for delivering other biological payloads across the cell membrane into cells. To date, it has proved challenging for the Pharma industry to get biological payloads into the intracellular space, where the majority of candidate therapeutic targets reside, most of which have proved intractable with both biological approaches or with conventional ‘small molecule’ drugs.
To view Newsletter please download PDF below:
